518 related articles for article (PubMed ID: 25629742)
1. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
2. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
3. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
4. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
Grover S; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
[TBL] [Abstract][Full Text] [Related]
5. Comparative Cost-Effectiveness of Hypertension Treatment in Non-Hispanic Blacks and Whites According to 2014 Guidelines: A Modeling Study.
Vasudeva E; Moise N; Huang C; Mason A; Penko J; Goldman L; Coxson PG; Bibbins-Domingo K; Moran AE
Am J Hypertens; 2016 Oct; 29(10):1195-205. PubMed ID: 27172970
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
[TBL] [Abstract][Full Text] [Related]
7. A Round-Up on Cost-Effectiveness of Hypertension Therapy Based on the 2014 Guidelines.
Wani P; Blanco-Garcia C
Curr Cardiol Rep; 2016 Mar; 18(3):24. PubMed ID: 26841786
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk: A Markov Modeling Study.
Constanti M; Floyd CN; Glover M; Boffa R; Wierzbicki AS; McManus RJ
Hypertension; 2021 Feb; 77(2):682-691. PubMed ID: 33342242
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
[TBL] [Abstract][Full Text] [Related]
13. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
15. Organized blood pressure control programs to prevent stroke in Australia: would they be cost-effective?
Cadilhac DA; Carter R; Thrift AG; Dewey HM
Stroke; 2012 May; 43(5):1370-5. PubMed ID: 22363058
[TBL] [Abstract][Full Text] [Related]
16. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis.
Sheppard JP; Fletcher K; McManus RJ; Mant J
Br J Gen Pract; 2014 Oct; 64(627):e641-8. PubMed ID: 25267050
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of Intensive Blood Pressure Management.
Richman IB; Fairley M; Jørgensen ME; Schuler A; Owens DK; Goldhaber-Fiebert JD
JAMA Cardiol; 2016 Nov; 1(8):872-879. PubMed ID: 27627731
[TBL] [Abstract][Full Text] [Related]
20. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
